Abstract
Inhibiting pathological secretion of Interleukin-1β has shown beneficial effects in disease models and in the clinic and thus there is interest in finding inhibitors that can reduce its release from macrophages in response to their activation by foreign pathogens. We used an in vitro human macrophage model to investigate whether ICRF-193, a Topoisomerase II inhibitor could modulate IL1B mRNA expression and IL-1β secretion. These macrophage-like cells readily secrete IL-1β in response to Lipopolysaccharide (LPS). Upon exposure to a non-toxic dose of ICRF-193, IL-1β secretion was diminished by ~ 40%; however, level of transcription of IL1B was unaffected. We show that there was no Topoisomerase 2B (TOP2B) binding to several IL1B gene sites, which may explain why ICRF-193 does not alter IL1B mRNA levels. Hence, we show for the first time that ICRF-193 can reduce IL-1β secretion. Its low cost and the development of water-soluble prodrugs of ICRF-193 warrants its further investigation in the modulation of pathological secretion of this cytokine for the treatment of inflammatory disorders. (165 words).
Similar content being viewed by others
Avoid common mistakes on your manuscript.
INTRODUCTION
IL-1β is a pro-inflammatory cytokine with a wide range of biological effects and is produced and secreted by several cell types such as macrophages, B lymphocytes, natural killer cells, smooth muscle cells and fibroblasts [1, 2]. Although IL-1β is essential for host-responses to infection and injury, it also exacerbates damage during acute tissue injury and in chronic inflammatory diseases such as cardiovascular disease, osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, type 2 diabetes, multiple sclerosis, and Alzheimer's disease [3, 4]. Hence, therapeutic strategies that suppress the release of IL-1β offer a strategy to regulate inflammation to reduce organ damage and fibrosis [5,6,7].
Recently, 24 h treatments with low dose Epirubicin (0.17 μM), an anthracycline poison of topoisomerase II (TOP2), has been shown to reduce inflammatory release of IL-1β by macrophages by down-regulating the NLRP3 inflammasome components and reducing the release of cleaved caspase-1. Suppression of transcription of LPS dependent genes with concomitant reduced acetylation of histone 3 lysine 9 (H3K9ac) was also observed [8]. Previously, Epirubicin has been shown to interact with histone H3 and inhibit acetylation of K9/K14 resulting in more compact and transcriptionally repressed chromatin [9]. In addition, anthracyclines have been shown to evict histones from particular regions in the genome, causing epigenomic and transcriptional alterations and attenuated double-strand break (DSB) repair [10,11,12,13]. Epirubicin has also been shown to bind to G-C sequences with higher affinity and can inhibit the formation of the transcription pre-initiation complex [9]. Thus, epirubicin can modulate chromatin structure and function.
Epirubicin is also a TOP2 poison. TOP2 enzymes can relieve DNA torsional stress in chromosomes caused by the unwinding of double stranded DNA during normal cellular processes such as replication, transcription, recombination and repair [14,15,16]. TOP2 achieves this by creating a transient double-strand break in the DNA duplex through which another duplex is passed before the break is resealed [17]. Epirubicin prevents TOP2-mediated DNA strand religation and results in a DSB associated with the enzyme [18, 19].
Mammalian cells encode two isoforms of TOP2; TOP2A and TOP2B whose genes have been mapped to q12-21 on chromosome 17 and p24 on chromosome 3, respectively [20]. A study using Nalm-6WT, Nalm-6 TOP2A ± and Nalm-6 TOP2B-/- showed that epirubicin mediates its toxicity mainly through TOP2A [21] and this was supported by a later study using the TARDIS assay which showed very few TOP2B epirubicin stabilised cleavage complexes in comparison to TOP2A using 10 μM epirubicin [22].
TOP2 isoforms are structurally similar, possessing 68% amino acid sequence identity, with 77% of that being conserved in the N-terminal domain [23]. They also appear to be biochemically similar, sharing the same catalytic cycle; however they play different roles in the cell. For example, TOP2A plays an indispensable role in genome replication and mitotic segregation by relieving torsional stress and preventing intertwining of daughter DNA molecules. TOP2 enzymes, particularly TOP2B, also participate in facilitating gene transcription [24,25,26,27,28]. Indeed, inhibition of TOP2B results in ~ 30% of the genes involved in neuronal development to be down-regulated [25] and this is supported by the non-viable TOP2B knockout mouse model [29], which demonstrated abnormal neuronal development. It has also been reported that TOP2B not only preferentially bound to regions containing high H3K4 methylation but also promoters that actively recruit RNA polymerase, both of which are features of transcriptionally active chromatin [30].
Given the role of TOP2 it is conceivable that the attenuation of IL-1β secretion and expression, as seen with epirubicin, could also be mediated in part by the modulation of TOP2 activity. For example, it has been shown that a 30-min exposure to 10 μM epirubicin could inhibit the ability of purified TOP2A and TOP2B from decatenating kinetoplast DNA in vitro [22]. To further understand if this is the case we used ICRF-193, a TOP2 inhibitor, to test for mitigation of IL-1β secretion and expression. ICRF-193 is a Bisdioxopiperazine and is non-DNA-intercalating, unlike epirubicin. The drug binds to the interface between TOP2 subunits formed when ATP or ADP is bound, thereby inducing the formation of a closed clamped intermediate of TOP2 on the DNA [31, 32]. ICRF-193 targets both isoforms of TOP2 with a preference for TOP2B [33]. In contrast to TOP2 poisons such as epirubicin, Bisdioxopiperazines have limited anti-cancer activity and only a prolonged period of exposure results in DNA break-related and DNA break-unrelated cellular damage [34, 35]. Instead they are primarily used to attenuate anthracycline cardiotoxicity in the clinic [36]. However as they are the most specific inhibitors of TOP2 that are not TOP2 poisons, they are an essential implement for studying the effect of inhibiting TOP2 [37].
The effect of ICRF-193 on IL-1β secretion and expression was investigated using the continuous human cell line U937, differentiated into a macrophage-like cell type using PMA, a synthetic phorbol ester [38,39,40]. Although the use of Monocyte-derived Macrophages help overcome the innate difficulties working with primary macrophages such as invasive harvesting methods, heterogeneity and lack of longevity in culture [41,42,43], it should be noted that the choice of isolation method and differentiating agent can significantly impact cellular phenotype and thus comparisons must be made with care [44]. Nevertheless, we show that these macrophage-like cells readily secrete IL-1β in response to LPS exposure and that upon exposure to a non-toxic dose of ICRF-193, IL-1β secretion was attenuated but transcription of IL1B remained unchanged. We show that there was no TOP2B binding to several IL1B gene proximal sites, confirming that TOP2B is not involved directly in mediating the transcription of IL1B at these sites and hence why ICRF-193 does not alter IL1B mRNA levels. We also show that cells in this model system have reduced levels of TOP2A and TOP2B mRNA compared to their non-differentiated counterparts; however, only TOPA protein levels showed a significant decrease. Ex vivo differentiated monocytes derived from peripheral blood also generally displayed this reduction in TOP2A and TOP2B mRNA levels. Hence, ICRF-193 merits further investigation as a promising drug candidate for controlling IL-1β secretion in inflammatory disorders.
MATERIALS AND METHODS
Cell Culture
The U937 cell line was derived from a 37-year-old Caucasian male suffering from histiocytic lymphoma and is characterised as being monocytic. Cells were maintained as a suspension culture in RPMI 1640 medium supplemented with 10% foetal calf serum (FCS), penicillin (50 U/ml), streptomycin (50 µg/ml) and glutamine (2 mM). Cells and were grown at concentrations between 1 × 105/ml and 1 × 106/mL and were free of mycoplasma contamination. Cells were cultured at 37 °C, 5% CO2 in a humidified atmosphere. Cell culture reagents were obtained from GIBCO, Life Technologies.
Peripheral Blood Mononuclear Cell (PBMC) Isolation
A qualified phlebotomist obtained 50 ml of venous blood from consenting healthy volunteers. Ethical approval was obtained from Northumbria University (project reference: SUB86_AJ_0511). Whole blood was added to a Leucosep tube (Greiner) and centrifuged for 12 min at 700 × g with no deceleration. The buffy coat layer was removed and mixed with 50 ml of FCS free-RPMI-1640 and centrifuged at 600 × g for 10 min with maximum deceleration. The supernatant was then discarded, and the remaining cells were re-suspended in 2 ml of FCS free-RPMI-1640.
CD14 Selection of PBMCs
1 × 107 cells were re-suspended in 50 μl of selection buffer (2 mM EDTA/PBS pH 7.2, 0.5% FCS). 20 μl of CD14 Microbeads (Miltenyi Biotec) were then added to the suspension of cells, mixed and incubated for 15 min at 4 °C. 1.5 ml of selection buffer was then added to the suspension of cells, this was followed by centrifugation at 1500 rpm for 5 min. The supernatant was removed, and cells were re-suspended in 500 μl of selection buffer. At this time a MACS MS + /RS + column was applied to the MACS separator and washed with 500 μl of selection buffer. The cell sample was then added and flow through was discarded. The column was then washed a further 3 times with 500 μl of selection buffer. The column was then removed from the MACS separator and 1 ml of buffer was used to flush out the CD14 + cells.
Quantitation of CD11b Surface Antigen Expression using Flow Cytometry
U937 cells were harvested and washed twice with PBS containing 0.1% FCS. Cells were then transferred to a FACs tube (Sarstedt) and centrifuged at 1000 rpm for 5 min. PBS was removed and cells were re-suspended in 20 μl of fresh PBS containing 0.1% FCS. 2 μl of Anti-CD11b –APC conjugated antibody (eBioscience 17–0118-41) was then added. Cells were gently mixed and allowed to incubate for 30 min in the dark. Samples were then washed twice with 1 ml PBS and re-suspended in 300 μl PBS. Flow cytometry was then performed.
Cell Cycle Analysis using Flow Cytometry
U937 were harvested and washed twice with PBS. Cells were then re-suspended in 200 μl PBS and added dropwise to 2 ml of ice cold 70% ethanol in PBS. Cells were fixed for 30 min at 4 °C. The fixative was then removed, and the cells were resuspended in 1 ml of PBS containing 0.2 μg/ml RNase A and 10 μg/μl propidium iodide. Cells were then incubated for 30 min at 37 °C. Flow cytometry was then performed.
XTT Assay
50 μl of XTT (1 mg/ml in RPMI-1640) and PMS (25 μM in PBS) reagent was added to 200 μl of cells and incubated at 37 °C, 5% CO2 in a humidified atmosphere for 4 h. The endpoint absorbance was then read at 450 nm and 630 nm on a spectrophotometer (Synergy, BioTek). Percentage cell viability was determined by the following calculation:
Trypan Blue Exclusion
Light microscopic quantitation of cell viability was carried out using a previously published method [45].
ELISAs
Quantification of IL-1β released into the supernatant was performed using the Ready-Set-Go ELISA kit to human Il-1β (eBioscience). A 96 well ELISA plate was coated overnight at 4 °C with an Il-1β capture antibody. The wells were then aspirated and washed 5 times (PBS, 0.05% Tween20.) Standard samples and experimental samples were then added to the plate in triplicate and the plate was then incubated for 2 h at room temperature. The wells were then aspirated and washed 3 times as before. IL-1β detection antibody was added to the plate and incubated for 1 h at room temperature. Wells were again aspirated and washed 5 times as before. The avidin–HRP enzyme was then added to the plate and incubated for 30 min at room temperature before the wells were aspirated and washed 7 times as before. 100 μl of substrate solution was then added to each well and the plate was left to incubate for a further 15 min. 50 μl of 2 M H2SO4 was then added to each well to stop the reaction. The plate was then read at 450 nM and 570 nM on a spectrophotometer (Synergy, BioTek).
Western Blotting
Cells were collected at 72 h following treatments and whole cell extracts were prepared [46]. Equal protein loads were applied to each lane and proteins separated using SDS-PAGE. TOP2A was detected with rabbit anti-TOP2A IgG (Sigma AV04007), TOP2B was detected using Mouse anti-TOP2B IgG (BD Bioscience 611,493), GAPDH was detected with rabbit anti-GAPDH IgG (Abcam ab9485) and Actin was detected using mouse anti-actin IgG (Thermo Scientific AC15). Pre-stained molecular weight markers were purchased from Biorad, UK (#1,610,374).
Quantitative Real-time PCR of TOP2A and TOP2B mRNA
RNA extraction was performed using the High Pure RNA Isolation kit (Roche). Synthesis of cDNA from RNA was performed using the Precision nanoscript reverse transcription kit (PrimerDesign). qPCR was performed using the C1000 Thermal Cycler BIO-RAD CFX96 Real time system using the following Taqman Primer Design hydrolysis probes:
TOP2A: Forward: TGGATTTGGATTCAGATGAAGATTT.
Reverse: CTAAGTTTTGGGGAAGTTTTGGT.
TOP2B: Forward: ATATGTCTCTGTGGTCTCTTACTAAA.
Reverse: GCCGCTAAATCCTCTTTCCAA.
Analysis was performed using the comparative ΔΔCt method [47] to determine relative fold expression between stimulations. 18S RNA was used as the reference gene [48].
Chromatin Immunoprecipitation (ChIP)
ChIP was performed using the EZ-Magna ChIP A, 17–408 kit (Millipore) and performed according to the manufacturer’s protocol. Briefly, differentiated U937 cells were exposed to LPS (Sigma-Aldrich) for 72 h. Treated and untreated control cells were then fixed using formaldehyde (1%, Sigma-Aldrich) and then neutralised with glycine. Cells were then washed twice in PBS containing protease inhibitors before lysis. Chromatin was fragmented to between 500 – 1000 bp using sonication (14 × 15 s cycles). 5% of the sample was removed as ‘input’. Anti-TOP2B (30,400), or anti-GFP (Santa Cruz Biotechnology, sc-8334) or anti-AcH3 (Millipore, 06-599B) were added to protein A magnetic beads (Invitrogen, 100.02D) and incubated for 30 min at room temperature. Chromatin samples were then added to the beads and incubated for 18 h at 4 °C. Protein A Magnetic beads were then separated from the rest of the sample using a magnetic separator. Immunoprecipitated protein-DNA complexes were then washed sequentially in a series of wash buffers provided in the Magna EZ ChIP kit as follows; Low salt Immune Complex Wash buffer, High Salt Immune Complex Wash buffer, LiCl Immune Complex Wash buffer and TE Buffer, allowing 5 min for incubation for each wash. Crosslinks in all samples including the ‘input’ were reversed by incubation in elution buffer with Proteinase K for 3 h at 62 °C with rotation. The samples were then heated to 95 °C for 10 min. DNA was then purified using a spin column (Millipore). qPCR was performed using iQ SYBR green supermix (Bio-Rad, 10,003,253), primers are shown in Table 1. Results were quantified as % input with GFP and AcH3% input values being the negative and positive controls, respectively.
Results
As all macrophages, including classically activated macrophages (M1) and alternative activated macrophages (M2), are known to express the cell surface antigen, CD11b [49, 50], this was used as a marker of differentiation of the U937 cells into a macrophage-like state. To determine the optimal PMA exposure time to induce the cell type to the terminal monocytic differentiated state, CD11b levels were monitored as levels steadily increase through the differentiation stages [51]. Results showed that CD11b expression was highest at 72 h (Fig. 1a) and showed significantly upregulated CD11b expression (Fig. 1b).
Increased expression of CD11b was also accompanied by a reduction in cell proliferation, as measured by trypan blue exclusion (Fig. 1c), and an increase in the visual granularity and size of the cells (Fig. 1d). In addition, an increase in the proportion of cells in G2M consistent with the macrophage-like phenotype was also seen in these cells (Fig. 1e) [52]. Cells also became adherent. Taken together, these results confirmed a differentiated-like phenotype. Cells exposed to PMA for 72 h also secreted bioactive Il-1β as measured by ELISA (Fig. 1f). When co-incubated with LPS, which polarizes the cells towards the M1 phenotype, more Il-1β secretion is noted in line with previous studies [53, 54]. However levels of secreted IL-1β are lower than many published studies which use shorter pulses of higher dose LPS ranging from 100 – 1000 ng/ml [55, 56]. A low dose of LPS was selected as subsequent experiments using co-treatment with LPS and ICRF-193 were chronic 72 h exposures and we wished to avoid a change of cellular phenotype from pro- to anti-inflammatory [57, 58].
During cellular differentiation, the level of both TOP2 isoforms are known to change [59,60,61,62,63], therefore to ascertain the levels of the two isoforms in U937 cells following treatment with PMA alone, TOP2A and TOP2B protein and mRNA levels were semi-quantified (Fig. 2).
TOP2A and TOP2B mRNA levels both decreased significantly upon treatment with PMA for 72 h and was accompanied by a decrease in both proteins; however, only TOPA protein levels showed a significant decrease. A reduction in TOP2B mRNA is seldom reported in the literature in differentiated versus non-differentiated cells, with most reporting an upregulation [25, 30, 59]. This reduction may be a cell type specific phenomenon, so we investigated whether this decrease in both TOP2A and TOP2B mRNA is also seen in normal peripheral blood monocytes when differentiated. To do this, we isolated monocytes from the blood of healthy volunteer donors and differentiated them using M-CSF alone and quantified TOP2A and TOPB mRNA levels using qPCR (Fig. 3).
TOP2A mRNA could be detected in only half of the non M-CSF samples examined and no TOP2A mRNA was seen in all of the samples cells exposed to M-CSF, except one. In contrast TOP2B mRNA was detected in all of the non M-CSF samples examined. However, the levels of TOP2B mRNA in M-CSF treated cells from donors 2 and 4 show a decrease and data sets of donors 1 and 3 demonstrate a lack of amplification of TOP2B after treatment with M-CSF, suggesting that levels are so low they are undetectable. These results support data seen in the U937 cells that show TOP2B mRNA levels decrease when these cells are differentiated into macrophage-like cells.
To investigate the effect of inhibiting TOP2 on IL-1β secretion and expression levels, cells were co-treated with PMA, LPS and ICRF -193. Cells were exposed to either 1 nM or 150 nM ICRF-193. These doses were confirmed to be non-toxic to the PMA treated cells (Fig. 4).
U937 cells were co-treated with 1 nM or 150 nM ICRF-193, along with PMA and LPS for 72 h and human IL-1β protein secretion and levels of expression were made using ELISA and qRT-PCR, respectively (Fig. 5).
IL-1β release was reduced by 41% (p = 0.03, student t-test) by treatment with 150 nM ICRF-193 (Fig. 5a). However, the attenuation of IL-1β protein secretion by ICRF-193 was not mediated at the level of IL1B mRNA as levels were unaffected by the treatments, as shown in Fig. 5b. As TOP2B is known to be involved in mediating transcription of some genes [24,25,26,27,28], and as ICRF-193 has a preference for inhibiting this isoform [33] and causing its degradation [64, 65], we wanted to confirm that TOP2B was not involved with transcription of IL1B. ChIP-qPCR was therefore utilised to analyse any TOP2B interactions with the IL1B promoter (Fig. 6). Three primer pairs used in the analysis were designed based on known DNAse hypersensitivity sites and putative TOP2B cleavage sites within the IL1B gene promoter (Fig. 6a-c). IL1B control primers (Fig. 6d) were designed to amplify regions which did not contain a DNase hypersensitivity or a putative TOP2B binding site and was located downstream of the promoter region within the gene [30].
Results showed that there was no significant difference in TOP2B association between the non-LPS treated samples and the LPS treated samples when using any of the primer pairs designed to amplify regions proximal to the promoter, thus suggesting there is little or no detectable TOP2B at the region of the IL1B gene that the primers amplify. Percentage input of the matching positive controls in the presence of LPS were significantly higher than both that seen with the TOP2B primers or the negative controls (GFP).
Discussion
We sought to determine if the inhibition of TOP2 activity would decrease IL-1β secretion and expression, and confirmed that ICRF-193, a TOP2 inhibitor, significantly decreased the amount of bioactive IL-1β secreted by cells displaying a macrophage-like phenotype, as measured by ELISA. Cells that had been co-treated with 150 nM ICRF-193, PMA and LPS for 72 h displayed a significant decrease of 41% in IL-1β protein secretion (p = 0.03). However, unlike epirubicin, a TOP2 poison and DNA intercalator, expression of IL1B mRNA was unaffected by treatment with this drug. This suggests that TOP2 is not involved in modulating IL1B mRNA expression. As TOP2B is the major isoform that is involved in transcriptional regulation [24,25,26,27,28], it was decided to test if TOP2B was associated with the promoter region of IL1B in the presence of LPS. ChIP experiments confirmed that TOP2B was not associated with the specific regions tested, suggesting that TOP2B may not be involved in transcription of IL1B in response to LPS stimulation in these cells which may explain why these doses of ICRF-193 do not inhibit transcription of IL1B. However, ChIP-sequencing would be needed to identify if other TOP2B binding sites occur across the IL1B gene to fully explore this. In addition direct interaction between TOP2B and ICRF-193 in this context would require verification and whether its disruption leads to secretion of normal levels of IL-1β.
Although TOP2A and TOP2B mRNA levels both decreased significantly upon treatment with PMA for 72 h, only TOPA protein levels showed a significant decrease, suggesting that levels of TOP2B protein remain available to inhibition by ICRF-193. In contrast to this present data many studies using both primary and continuous cells have shown that TOP2B mRNA and protein level are increased upon differentiation [29, 30, 59]. For example, it has been reported that differentiation of HL-60 cells using all-trans retinoic acid resulted in an increase in TOP2B protein [66]. TOP2B protein expression was also up-regulated when NB4 and NB4-MR2 cells were treated with PMA for 2 h, and that an increase in protein expression correlated with an increase in PMA concentration [67]. This study also postulated that this up-regulation could be the result of an up-regulation of protein kinase delta (PKCD), which is stimulated by PMA, and suggests that PKCD phosphorylates TOP2B protein leading to an increase in stability and a decreased rate of degradation. Inhibition of PKCD was also shown to result in a decrease in TOP2B protein level [67]. This could account for why there is a decrease in TOP2B mRNA and yet no significant change in the level of TOP2B protein when U937 cells are exposed to PMA for 72 h. However, in an earlier study using HL-60 cells, levels of TOP2B were shown to be reduced upon differentiation with DMSO [68]. The difference in TOP2B levels observed between the studies may be due to the differentiating agent used as well as cell type and the timeframe examined. For example, TOP2B has been shown to be required for late but not early neuronal development and that changes in the level of TOP2B could change over the process of differentiation [25].
Relative levels of TOP2A and TOP2B mRNA were also examined in primary monocytes differentiated ex-vivo using M-CSF. M-CSF acts by indirectly activating Protein Kinase C (PKC) by inducing the production of diacylglycerol (DAG) [69, 70]. The activation of PKC causes a cascade of events leading to activation of transcription factors, and therefore transcription of genes involved in differentiation. This pathway of activation is very similar to that of PMA as PMA is analogous to DAG [71], thus being able to stimulate PKC directly. TOP2A mRNA could be detected in only half of the non M-CSF samples examined. This is not unexpected as previously only very low levels of TOP2A mRNA levels were detected in peripheral blood mononuclear cells from healthy volunteers with levels equating to only ~ 2.5% of the TOP2B mRNA levels seen in the same cells [72]. As well as the known variability of cells between donors [73], CD14 + monocytes do not proliferate [74], thus TOP2A expression level is expected to be low per se [75, 76]. No TOP2A mRNA was seen in all of the samples cells exposed to M-CSF, except one. This suggests that differentiation into the macrophage-like phenotype, generally results in a reduction of TOP2A mRNA. A down regulation of TOP2A mRNA was also demonstrated when primary monocytes underwent differentiation with M-CSF using transcriptome analysis [77]. In contrast TOP2B mRNA was detected in all of the non M-CSF samples examined. Similarly TOP2B mRNA was detectable in peripheral blood cells from all health volunteers and its level varied threefold between volunteers [72]. In all of the four samples treated with M-CSF, levels of TOP2B mRNA reduced. In 50% of the samples, TOP2B mRNA dropped to less than half of that detected in untreated cells and with TOP2B mRNA becoming undetectable in the other 50%. These results are similar to those seen in the cell lines used in the current study (Fig. 2). It would be useful to measure TOP2A and TOP2B protein levels in these cells to determine if the mRNA levels correlate to relative level of proteins. Interestingly several studies have shown a decline in levels of TOP2B protein as cells enter G0, although in contrast to TOP2A, TOP2B protein remains detectable at this time [63, 78, 79].
From our results we suggest that IL1B transcriptional silencing seen with epirubicin is not due to the inhibition of TOP2 enzymatic activity. Nevertheless, ICRF-193 does attenuate secretion of bioactive IL-1β. How ICRF-193 does this is yet unknown, but one hypothesis may be that it inhibits stimulus-induced IL-1β post-translational processing. This could be via a variety of mechanisms, for example by inhibiting the NLRP3 inflammasome either by direct interaction [80] or by down-regulating the NLRP3 inflammasome components and reducing the release of cleaved caspase-1 via modulation of chromatin structure and function [8,9,10,11,12,13]. It is also possible that ICRF-193 may promote ubiquitination and degradation of inflammatory caspases. Recently, the small molecule kaempferol and a bacterial effector protein have both been observed to do just this and attenuate IL-1β secretion [81, 82] Further studies are needed to examine if ICRF-193 promotes ubiquitination and restraint of the inflammasome and also if it’s effect can be potentiated by using it in combination with other such drugs. In addition it is possible that such effects of ICRF-193 may be visible at earlier time points than those measured in this study. Interestingly, ICRF-193 has also been shown to cause degradation of TOP2B protein via the proteasome but not TOP2A [64, 65]. However, these studies have only explored the effect of ICRF-193 up to a maximum of 12 h and at much higher doses. It is also possible that ICRF-193 can alter indirect components which inhibit the inflammasome. For example, Doxorubicin, another anthracycline TOP2 poison, increased expression levels of the dopamine receptor DRD1, which in the presence of an agonist decreased the activation of the inflammasome, attenuating release of IL-1β [83].
In summary, the results provide a novel finding that inhibition of TOP2 activity by ICRF-193 can attenuate the secretion of IL-1β, which warrants further investigation of the mechanism and whether this drug could be further investigated for the treatment of inflammatory disorders. Recently, more water soluble prodrugs of ICRF-193 have been synthesised and show promise pharmaceutically as they display low cytotoxicity and favourable ICRF-193 release [84, 85]. Their ease of synthesis is also important as it represents a cheaper alternative to other recombinant antagonists [86].
Data Availability
Data is available upon request.
References
Garlanda, C., C.A. Dinarello, and A. Mantovani. 2013. The interleukin-1 family: Back to the future. Immunity 39 (6): 1003–1018. https://doi.org/10.1016/j.immuni.2013.11.010.
Voet, S., S. Srinivasan, M. Lamkanfi, and G. van Loo, 2019. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Molecular Medicine 11 (6): e10248. https://doi.org/10.15252/emmm.201810248.
Menu, P., and J.E. Vince. 2011. The NLRP3 inflammasome in health and disease: The good, the bad and the ugly. Clinical and Experimental Immunology 166 (1): 1–15. https://doi.org/10.1111/j.1365-2249.2011.04440.x.
Strowig, T., J. Henao-Mejia, E. Elinav, and R. Flavell. 2012. Inflammasomes in health and disease. Nature 481 (7381): 278–286. https://doi.org/10.1038/nature10759.
Dinarello, C.A., A. Simon, and J.W. van der Meer. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews. Drug Discovery 11 (8): 633–652. https://doi.org/10.1038/nrd3800.
Shakoory, B., J.A. Carcillo, W.W. Chatham, R.L. Amdur, H. Zhao, C.A. Dinarello, R.Q. Cron, and S.M. Opal. 2016. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Critical Care Medicine 44 (2): 275–281. https://doi.org/10.1097/CCM.0000000000001402.
Cavalli, G., G. De Luca, C. Campochiaro, E. Della-Torre, M. Ripa, D. Canetti, C. Oltolini, B. Castiglioni, Din C. Tassan, N. Boffini, A. Tomelleri, N. Farina, A. Ruggeri, P. Rovere-Querini, G. Di Lucca, S. Martinenghi, R. Scotti, M. Tresoldi, F. Ciceri, G. Landoni, A. Zangrillo, P. Scarpellini, and L. Dagna. 2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2 (6): e325–e331. https://doi.org/10.1016/S2665-9913(20)30127-2.
Köse-Vogel, N., S. Stengel, E. Gardey, T. Kirchberger-Tolstik, P.A. Reuken, A. Stallmach, and T. Bruns. 2019. Transcriptional Suppression of the NLRP3 Inflammasome and Cytokine Release in Primary Macrophages by Low-Dose Anthracyclines. Cells 9 (1): 79. https://doi.org/10.3390/cells9010079.
Khan, S.N., M. Danishuddin, B. Varshney, S.K. Lal, and A.U. Khan. 2012. Inhibition of N-terminal lysines acetylation and transcription factor assembly by epirubicin induced deranged cell homeostasis. PLoS One 7 (12): e51850. https://doi.org/10.1371/journal.pone.0051850.
Yang, F., C.J. Kemp, and S. Henikoff. 2013. Doxorubicin enhances nucleosome turnover around promoters. Current Biology 23 (9): 782–787. https://doi.org/10.1016/j.cub.2013.03.043.
Pang, B., X. Qiao, L. Janssen, A. Velds, T. Groothuis, R. Kerkhoven, M. Nieuwland, H. Ovaa, S. Rottenberg, O. van Tellingen, J. Janssen, P. Huijgens, W. Zwart, and J. Neefjes. 1908. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications 2013: 4. https://doi.org/10.1038/ncomms2921.
Pang, B., J. de Jong, X. Qiao, L.F. Wessels, and J. Neefjes. 2015. Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nature Chemical Biology 11 (7): 472–480. https://doi.org/10.1038/nchembio.1811.
Nesher, E., A. Safina, I. Aljahdali, S. Portwood, E.S. Wang, I. Koman, J. Wang, and K.V. Gurova. 2018. Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Research 78 (6): 1431–1443. https://doi.org/10.1158/0008-5472.CAN-17-2690.
Champoux, J.J. 2001. DNA topoisomerases: Structure, function, and mechanism. Annual Review of Biochemistry 70: 369–413. https://doi.org/10.1146/annurev.biochem.70.1.369.
McClendon, A.K., A.C. Rodriguez, and N. Osheroff. 2005. Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: Implications for enzyme action ahead of replication forks. Journal of Biological Chemistry 280 (47): 39337–39345. https://doi.org/10.1074/jbc.M503320200.
Nitiss, J.L. 2009. DNA topoisomerase II and its growing repertoire of biological functions. Nature Reviews Cancer 9 (5): 327–337. https://doi.org/10.1038/nrc2608.
Austin, C.A., K.C. Lee, R.L. Swan, M.M. Khazeem, C.M. Manville, P. Cridland, A. Treumann, A. Porter, N.J. Morris, and I.G. Cowell. 2018. TOP2B: The First Thirty Years. International Journal of Molecular Sciences 19 (9): 2765. https://doi.org/10.3390/ijms19092765.
Cornarotti, M., S. Tinelli, E. Willmore, F. Zunino, L.M. Fisher, C.A. Austin, and G. Capranico. 1996. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). Molecular Pharmacology 50 (6): 1463–1471.
Marinello, J., M. Delcuratolo, and G. Capranico. 2018. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. International Journal of Molecular Sciences 19 (11): 3480. https://doi.org/10.3390/ijms19113480.
Tan, K.B., T.E. Dorman, K.M. Falls, T.D. Chung, C.K. Mirabelli, S.T. Crooke, and J. Mao. 1992. Topoisomerase II alpha and topoisomerase II beta genes: Characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Research 52 (1): 231–234.
Lee, K.C., R.L. Bramley, I.G. Cowell, G.H. Jackson, and C.A. Austin. 2016. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II. Biochemical Pharmacology 103: 29–39. https://doi.org/10.1016/j.bcp.2015.12.015.
Atwal, M., R.L. Swan, C. Rowe, K.C. Lee, D.C. Lee, L. Armstrong, I.G. Cowell, and C.A. Austin. 2019. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations. Molecular Pharmacology 96 (4): 475–484. https://doi.org/10.1124/mol.119.117259.
Austin, C.A., J.H. Sng, S. Patel, and L.M. Fisher. 1993. Novel HeLa topoisomerase II is the II beta isoform: Complete coding sequence and homology with other type II topoisomerases. Biochimica et Biophysica Acta 1172 (3): 283–291. https://doi.org/10.1016/0167-4781(93)90215-y.
Ju, B.G., V.V. Lunyak, V. Perissi, I. Garcia-Bassets, D.W. Rose, C.K. Glass, and M.G. Rosenfeld. 2006. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 312 (5781): 1798–1802. https://doi.org/10.1126/science.1127196.
Lyu, Y.L., C.P. Lin, A.M. Azarova, L. Cai, J.C. Wang, and L.F. Liu. 2006. Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Molecular and Cellular Biology 26 (21): 7929–7941. https://doi.org/10.1128/MCB.00617-06.
Vos, S.M., E.M. Tretter, B.H. Schmidt, and J.M. Berger. 2011. All tangled up: How cells direct, manage and exploit topoisomerase function. Nature Reviews Molecular Cell Biology 12 (12): 827–841. https://doi.org/10.1038/nrm3228.
King, I.F., C.N. Yandava, A.M. Mabb, J.S. Hsiao, H.S. Huang, B.L. Pearson, J.M. Calabrese, J. Starmer, J.S. Parker, T. Magnuson, S.J. Chamberlain, B.D. Philpot, and M.J. Zylka. 2013. Topoisomerases facilitate transcription of long genes linked to autism. Nature 501 (7465): 58–62. https://doi.org/10.1038/nature12504.
Yu, X., J.W. Davenport, K.A. Urtishak, M.L. Carillo, S.J. Gosai, C.P. Kolaris, J.A.W. Byl, E.F. Rappaport, N. Osheroff, B.D. Gregory, and C.A. Felix. 2017. Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci. Genome Research 27 (7): 1238–1249. https://doi.org/10.1101/gr.211615.116.
Lyu, Y.L., and J.C. Wang. 2003. Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta. Proceedings of the National Academy of Sciences (PNAS) 100 (12): 7123–7128. https://doi.org/10.1073/pnas.1232376100.
Tiwari, V.K., L. Burger, V. Nikoletopoulou, R. Deogracias, S. Thakurela, C. Wirbelauer, J. Kaut, R. Terranova, L. Hoerner, C. Mielke, F. Boege, R. Murr, A.H. Peters, Y.A. Barde, and D. Schübeler. 2012. Target genes of Topoisomerase IIβ regulate neuronal survival and are defined by their chromatin state. Proceedings of the National Academy of Sciences (PNAS) 109 (16): E934–E943. https://doi.org/10.1073/pnas.1119798109.
Morris, S.K., C.L. Baird, and J.E. Lbashirindsley. 2000. Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193. Journal of Biological Chemistry 275 (4): 2613–2618. https://doi.org/10.1074/jbc.275.4.2613.
Kawano, S., K. Fujimoto, K. Yasuda, and S. Ikeda. 2020. DNA binding activity of the proximal C-terminal domain of rat DNA topoisomerase IIβ is involved in ICRF-193-induced closed-clamp formation. PLoS One 15 (9): e0239466. https://doi.org/10.1371/journal.pone.0239466.
Shapiro, A.B., and C.A. Austin. 2014. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation. Analytical Biochemistry 448: 23–29. https://doi.org/10.1016/j.ab.2013.11.029.
Jensen, L.H., M. Dejligbjerg, L.T. Hansen, M. Grauslund, P.B. Jensen, and M. Sehested. 2004. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. BMC Pharmacology and Toxicology 4 (31). https://doi.org/10.1186/1471-2210-4-31.
Skoufias, D.A., F.B. Lacroix, P.R. Andreassen, L. Wilson, and R.L. Margolis. 2004. Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Molecular Cell 15 (6): 977–990. https://doi.org/10.1016/j.molcel.2004.08.018.
Stěrba, M., O. Popelová, A. Vávrová, E. Jirkovský, P. Kovaříková, V. Geršl, and T. Simůnek. 2013. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxidants & Redox Signaling 18 (8): 899–929. https://doi.org/10.1089/ars.2012.4795.
Nitiss, J.L. 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews Cancer 9 (5): 338–350. https://doi.org/10.1038/nrc2607.
Padilla, P.I., A. Wada, K. Yahiro, M. Kimura, T. Niidome, H. Aoyagi, A. Kumatori, M. Anami, T. Hayashi, J. Fujisawa, H. Saito, J. Moss, and T. Hirayama. 2000. Morphologic differentiation of HL-60 cells is associated with appearance of RPTPbeta and induction of Helicobacter pylori VacA sensitivity. Journal of Biological Chemistry 275 (20): 15200–15206. https://doi.org/10.1074/jbc.275.20.15200.
Ciubotaru, I., L.A. Potempa, and R.C. Wander. 2005. Production of modified C-reactive protein in U937-derived macrophages. Experimental Biology and Medicine 230 (10): 762–770. https://doi.org/10.1177/153537020523001010.
Jerke, U., S. Tkachuk, J. Kiyan, V. Stepanova, A. Kusch, M. Hinz, R. Dietz, H. Haller, B. Fuhrman, and I. Dumler, 2009. Stat1 nuclear translocation by nucleolin upon monocyte differentiation. PLoS One 4 (12): e8302. https://doi.org/10.1371/journal.pone.0008302.
Wetzka, B., D.E. Clark, D.S. Charnock-Jones, H.P. Zahradnik, and S.K. Smith. 1997. Isolation of macrophages (Hofbauer cells) from human term placenta and their prostaglandin E2 and thromboxane production. Human Reproduction 12 (4): 847–852. https://doi.org/10.1093/humrep/12.4.847.
Li, J., D.K. Pritchard, X. Wang, D.R. Park, R.E. Bumgarner, S.M. Schwartz, and W.C. Liles. 2007. cDNA microarray analysis reveals fundamental differences in the expression profiles of primary human monocytes, monocyte-derived macrophages, and alveolar macrophages. Journal of Leukocyte Biology 81 (1): 328–335. https://doi.org/10.1189/jlb.0206124.
Murray, P.J., J.E. Allen, S.K. Biswas, E.A. Fisher, D.W. Gilroy, S. Goerdt, S. Gordon, J.A. Hamilton, L.B. Ivashkiv, T. Lawrence, M. Locati, A. Mantovani, F.O. Martinez, J.L. Mege, D.M. Mosser, G. Natoli, J.P. Saeij, J.L. Schultze, K.A. Shirey, A. Sica, J. Suttles, I. Udalova, J.A. van Ginderachter, S.N. and T.A. Vogel Wynn, 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (1): 14–20. https://doi.org/10.1016/j.immuni.2014.06.008.
Nielsen, M.C., M.N. Andersen, and H.J. Møller. 2020. Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro. Immunology 159 (1): 63–74. https://doi.org/10.1111/imm.13125.
Strober, W. 2015. Trypan Blue Exclusion Test of Cell Viability. Current Protocols in Immunology 111: A3.B.1-A3.B.3. https://doi.org/10.1002/0471142735.ima03bs111
Mirski, S.E., C.D. Evans, K.C. Almquist, M.L. Slovak, and S.P. Cole. 1993. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Research 53 (20): 4866–4873.
Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (4): 402–408. https://doi.org/10.1006/meth.2001.1262.
Zhao, L., P. Ye, and T.J. Gonda. 2014. The MYB proto-oncogene suppresses monocytic differentiation of acute myeloid leukemia cells via transcriptional activation of its target gene GFI1. Oncogene 33 (35): 4442–4449. https://doi.org/10.1038/onc.2013.419.
Daigneault, M., J.A. Preston, H.M. Marriott, M.K. Whyte, and D.H. Dockrell. 2010. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5 (1): e8668. https://doi.org/10.1371/journal.pone.0008668.
Cui, K., C.L. Ardell, N.P. Podolnikova, and V.P. Yakubenko. 2018. Distinct Migratory Properties of M1, M2, and Resident Macrophages Are Regulated by αDβ2 and αMβ2 Integrin-Mediated Adhesion. Frontiers in Immunology 9: 2650. https://doi.org/10.3389/fimmu.2018.02650.
Van Lochem, E.G., V.H. van der Velden, H.K. Wind, J.G. te Marvelde, N.A. Westerdaal, and J.J. van Dongen. 2004. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts. Cytometry. Part B, Clinical Cytometry 60 (1): 1–13. https://doi.org/10.1002/cyto.b.20008.
Gažová, I., L. Lefevre, S.J. Bush, S. Clohisey, E. Arner, M. de Hoon, J. Severin, L. van Duin, R. Andersson, A. Lengeling, D.A. Hume, and K.M. Summers. 2020. The Transcriptional Network That Controls Growth Arrest and Macrophage Differentiation in the Human Myeloid Leukemia Cell Line THP-1. Frontiers in Cell and Developmental Biology 8: 498. https://doi.org/10.3389/fcell.2020.00498.
Genin, M., F. Clement, A. Fattaccioli, M. Raes, and C. Michiels. 2015. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 15: 577. https://doi.org/10.1186/s12885-015-1546-9.
Tusiimire, J., J. Wallace, N. Woods, M.J. Dufton, J.A. Parkinson, G. Abbott, C.J. Clements, L. Young, J.K. Park, J.W. Jeon, V.A. Ferro, and D.G. Watson. 2016. Effect of Bee Venom and Its Fractions on the Release of Pro-Inflammatory Cytokines in PMA-Differentiated U937 Cells Co-Stimulated with LPS. Vaccines (Basel). 4 (2): 11. https://doi.org/10.3390/vaccines4020011.
Torretta, S., A. Scagliola, L. Ricci, F. Mainini, S. Di Marco, I. Cuccovillo, A. Kajaste-Rudnitski, D. Sumpton, K.M. Ryan, and S. Cardaci. 2020. D-mannose suppresses macrophage IL-1β production. Nature Communications 11 (1): 6343. https://doi.org/10.1038/s41467-020-20164-6.
Wang, X., H. Xu, Y. Wang, C. Shen, L. Ma, and C. Zhao. 2020. MicroRNA-124a contributes to glucocorticoid resistance in acute-on-chronic liver failure by negatively regulating glucocorticoid receptor alpha. Annals of Hepatology 19 (2): 214–221. https://doi.org/10.1016/j.aohep.2019.08.007.
Vergadi, E., K. Vaporidi, and C. Tsatsanis. 2018. Regulation of endotoxin tolerance and compensatory anti-inflammatory response syndrome by non-coding RNAs. Frontiers in Immunology 9. https://doi.org/10.3389/fimmu.2018.02705.
Faia., C., K. Plaisance-Bonstaff, C. Vittori, D. Wyczechowska, A. Lassak, M. Meyaski-Schluter, K. Reiss, and F. Peruzzi. 2021. Attenuated Negative Feedback in Monocyte-Derived Macrophages From Persons Living With HIV: A Role for IKAROS. Frontiers in Immunology 30 (12): 785905. https://doi.org/10.3389/fimmu.2021.785905.
Tsutsui, K., K. Tsutsui, K. Sano, A. Kikuchi, and A. Tokunaga. 2001. Involvement of DNA topoisomerase IIbeta in neuronal differentiation. Journal of Biological Chemistry 276 (8): 5769–5778. https://doi.org/10.1074/jbc.M008517200.
Capranico, G., S. Tinelli, C.A. Austin, M.L. Fisher, and F. Zunino. 1992. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochimica et Biophysica Acta 1132 (1): 43–48. https://doi.org/10.1016/0167-4781(92)90050-a.
Tsutsui, K., K. Tsutsui, S. Okada, M. Watanabe, T. Shohmori, S. Seki, and Y. Inoue. 1993. Molecular cloning of partial cDNAs for rat DNA topoisomerase II isoforms and their differential expression in brain development. Journal of Biological Chemistry 268 (25): 19076–19083.
Zwelling, L.A., M. Hinds, D. Chan, E. Altschuler, J. Mayes, and T.F. Zipf. 1990. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation. Cancer Research 50 (22): 7116–7122.
Woessner, R.D., M.R. Mattern, C.K. Mirabelli, R.K. Johnson, and F.H. Drake. 1991. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth & Differentiation 2 (4): 209–214.
Isik, S., K. Sano, K. Tsutsui, M. Seki, T. Enomoto, H. Saitoh, and K. Tsutsui. 2003. The SUMO pathway is required for selective degradation of DNA topoisomerase IIbeta induced by a catalytic inhibitor ICRF-193(1). FEBS Letters 546 (2–3): 374–378. https://doi.org/10.1016/s0014-5793(03)00637-9.
Xiao, H., Y. Mao, S.D. Desai, N. Zhou, C.Y. Ting, J. Hwang, and L.F. Liu. 2003. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway. Proceedings of the National Academy of Sciences (PNAS) 100 (6): 3239–3244. https://doi.org/10.1073/pnas.0736401100.
Aoyama, M., D.R. Grabowski, R.J. Isaacs, K.A. Krivacic, L.A. Rybicki, R.M. Bukowski, M.K. Ganapathi, I.D. Hickson, and R. Ganapathi. 1998. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells. Blood 92 (8): 2863–2870.
McNamara, S., J.N. Nichol, H. Wang, and W.H. Miller Jr. 2010. Targeting PKC delta-mediated topoisomerase II beta overexpression subverts the differentiation block in a retinoic acid-resistant APL cell line. Leukemia 24 (4): 729–739. https://doi.org/10.1038/leu.2010.27.
Kaufmann, S.H., S.J. McLaughlin, M.B. Kastan, L.F. Liu, J.E. Karp, and P.J. Burke. 1991. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Research 51 (13): 3534–3543.
Valledor, A.F., J. Xaus, L. Marquès, and A. Celada. 1999. Macrophage colony-stimulating factor induces the expression of mitogen-activated protein kinase phosphatase-1 through a protein kinase C-dependent pathway. The Journal of Immunology 163 (5): 2452–2462.
Sánchez-Tilló, E., M. Comalada, C. Farrera, A.F. Valledor, J. Lloberas, and A. Celada. 2006. Macrophage-colony-stimulating factor-induced proliferation and lipopolysaccharide-dependent activation of macrophages requires Raf-1 phosphorylation to induce mitogen kinase phosphatase-1 expression. The Journal of Immunology 176 (11): 6594–6602. https://doi.org/10.4049/jimmunol.176.11.6594.
Teixeira, C., S.L. Stang, Y. Zheng, N.S. Beswick, and J.C. Stone. 2003. Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood 102 (4): 1414–1420. https://doi.org/10.1182/blood-2002-11-3621.
Kersting, G., M.V. Tzvetkov, K. Huse, B. Kulle, V. Hafner, J. Brockmöller, and L. Wojnowski. 2006. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn-Schmiedeberg’s Archives of Pharmacology 374 (1): 21–30. https://doi.org/10.1007/s00210-006-0091-0.
Tedesco, S., F. De Majo, J. Kim, A. Trenti, L. Trevisi, G.P. Fadini, C. Bolego, P.W. Zandstra, A. Cignarella, and L. Vitiello. 2018. Convenience versus Biological Significance: Are PMA-Differentiated THP-1 Cells a Reliable Substitute for Blood-Derived Macrophages When Studying in Vitro Polarization? Frontiers in Pharmacology 9: 71. https://doi.org/10.3389/fphar.2018.00071.
Clanchy, F.I., A.C. Holloway, R. Lari, P.U. Cameron, and J.A. Hamilton. 2006. Detection and properties of the human proliferative monocyte subpopulation. Journal of Leukocyte Biology 79 (4): 757–766. https://doi.org/10.1189/jlb.0905522.
Goswami, P.C., J.L. Roti Roti, and C.R. Hunt. 1996. The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Molecular and Cellular Biology 16 (4): 1500–1508. https://doi.org/10.1128/MCB.16.4.1500.
Lee, J.H., and J.M. Berger. 2019. Cell Cycle-Dependent Control and Roles of DNA Topoisomerase II. Genes (Basel). 10 (11): 859. https://doi.org/10.3390/genes10110859.
Martinez, F.O., S. Gordon, M. Locati, and A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. The Journal of Immunology 177 (10): 7303–7311. https://doi.org/10.4049/jimmunol.177.10.7303.
Turley, H., M. Comley, S. Houlbrook, N. Nozaki, A. Kikuchi, I.D. Hickson, K. Gatter, and A.L. Harris, 1997. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. British Journal of Cancer 75 (9): 1340–6. https://doi.org/10.1038/bjc.1997.227.
Padget, K., A.D. Pearson, and C.A. Austin. 2000. Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting. Leukemia 14 (11): 1997–2005. https://doi.org/10.1038/sj.leu.2401928.
Coll, R.C., A. Robertson, M. Butler, M. Cooper, and L.A. O'Neill, 2011. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS One 6 (12): e29539. https://doi.org/10.1371/journal.pone.0029539.
Han, X., S. Sun, Y. Sun, Q. Song, J. Zhu, N. Song, M. Chen, T. Sun, M. Xia, J. Ding, M. Lu, H. Yao, and G. Hu. 2019. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: Implications for Parkinson disease. Autophagy 15 (11): 1860–1881. https://doi.org/10.1080/15548627.2019.1596481.
Jakka, P., S. Namani, S. Murugan, N. Rai, and G. Radhakrishnan. 2017. The Brucella effector protein TcpB induces degradation of inflammatory caspases and thereby subverts non-canonical inflammasome activation in macrophages. Journal of Biological Chemistry 292 (50): 20613–20627. https://doi.org/10.1074/jbc.M117.815878.
Liu, J., Y. Jin, B. Wang, Y. Wang, S. Zuo, and J. Zhang. 2021. Dopamine D1 receptor alleviates doxorubicin-induced cardiac injury by inhibiting NLRP3 inflammasome. Biochemical and Biophysical Research Communications 561: 7–13. https://doi.org/10.1016/j.bbrc.2021.04.098.
Bavlovič, Piskáčková H., H. Jansová, J. Kubeš, G. Karabanovich, N. Váňová, P. Kollárová-Brázdová, I. Melnikova, A. Jirkovská, O. Lenčová-Popelová, J. Chládek, J. Roh, T. Šimůnek, M. Štěrba, and P. Štěrbová-Kovaříková. 2021. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity. Science and Reports 11 (1): 4456. https://doi.org/10.1038/s41598-021-83688-x.
Jirkovská, A., G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, Piskáčková H. Bavlovič, J. Škoda, M. Štěrba, C.A. Austin, T. Šimůnek, and J. Roh. 2021. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. Journal of Medicinal Chemistry 64 (7): 3997–4019. https://doi.org/10.1021/acs.jmedchem.0c02157.
Bashir, H., N. Ahmed, M.A. Khan, A.U. Zafar, S. Tahir, H. Kanwal, F. Khan, Z.U. Rahman, and T. Husnain. 2017. Evaluating the autoinduction expression system and one-step purification for high-level expression and purification of gallbladder-derived rhIL-1Ra. Biotechnology and Applied Biochemistry 64 (1): 20–26. https://doi.org/10.1002/bab.1463.
Acknowledgements
Grateful thanks are extended to Prof. C.A. Austin and her research group (Newcastle University, UK) for their guidance and provision of materials used for the ChIP analysis.
Funding
This research was funded by Northumbria University, UK and received no external funding.
Author information
Authors and Affiliations
Contributions
Conceptualization, K.P., A.B.; methodology, K.P., A.B.; formal analysis, A.B., K.P.; investigation, A.B., C.B., M.K., K.P, S.T.; writing—original draft preparation, K.P.; writing—review and editing, A.B., C.B., M.K., S.T.; supervision, K.P.; project administration, K.P.; funding acquisition, K.P. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Conflicts of Interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Brindle, A., Bainbridge, C., Kumar, M.R. et al. The Bisdioxopiperazine ICRF-193 Attenuates LPS-induced IL-1β Secretion by Macrophages. Inflammation 47, 84–98 (2024). https://doi.org/10.1007/s10753-023-01895-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-023-01895-2